GENERIC ANIMAL PHARMACEUTICALS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts
One day of correction and memories of January and February come flooding back. But let's be very clear: We are not going to see a phase where the Indian market is a standalone underperformer in the emerging market space. It does not mean we won't see volatility and corrections that are part of any bull run. Our assumption of bullishness is because the market's reaction to the Q4 earnings season has been better than expected. The street has rewarded companies (both large- and mid-caps) that had better-than-expected numbers. And punished those that did not.
Advent International to acquire stake in Felix Pharmaceuticals
Advent International is set to invest $175 million in Felix Pharmaceuticals, acquiring a significant minority stake. Felix Pharma, a Dublin-based company, specializes in generic animal pharmaceuticals, particularly for companion animals. With 14 USFDA-approved products and a robust pipeline, Felix aims to expand its global presence with Advent's support and expertise.
Specialty chemicals: Time for a re-look, as China negotiates & they integrate: 11 stocks, 6 with upside potential of over 27%
China Plus One is not quite making the headlines these days. But in the chemicals sector (both in speciality as well as commodity chemicals), underlying changes are happening at a reasonably strong pace that will bring it back into the limelight. These changes are focused on ensuring at least partial backward integration so that, over the medium term, dependence on Chinese imports comes down. This, however, will take time. And till it actually happens, there will be quarters, even years, when some of these companies will be under some pressure. So, a “Hold” phase, before these stocks turn into “Buys”.
A problem called dumping: 21 stocks from chemical & specialty chemical sector that may face business trouble in coming months
Global stock markets, including India, are focused on tariffs. Which is probably why we are missing a bigger and more immediate threat: Dumping. While the threat of dumping is omnipresent for Indian manufacturers, it is more acute in some sectors. Mind you, this is not about the possibility of dumping. It is about its certainty. There will be dumping of different products. The reason is simple: Domestic use of those products is limited in China. If they cannot export them to the US or other countries due to tariffs, they will have to dump them somewhere. Anti-dumping duties may seem like an antidote, but it is not as easy as it sounds.
Trump's reciprocal tariffs on India: Your one-stop guide to understand the impact on different industries
Indian industry and government officials remain uncertain if US President Trump's threat of reciprocal tariffs on trade partners, including India, will materialize on April 2. This move could significantly impact sectors spanning agriculture and industry, with varied tariff impacts, leading stakeholders to hope for deferred decisions and fair trade negotiations to minimize disruptions.
Sequent Scientific, Viyash Life Sciences explore merger worth Rs 7000-8000 cr
Sequent Scientific and Viyash Life Sciences are discussing a potential merger valued at Rs. 7000-8000 crore. Both companies' boards will meet to consider the deal, which could offer back-end synergies. Carlyle, a global private equity firm, holds shares in both firms. The merger aims to leverage Viyash's manufacturing capacity for Sequent's benefit.
- Go To Page 1
Fundamental Radar: Why Zydus Lifesciences is poised for strong earnings growth
Headquartered in Ahmedabad, Zydus Lifesciences is present across the pharmaceutical value chain of research, development, manufacturing, marketing, and sale of finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products.
Aurobindo Pharma says Rs 420 crore deal to acquire 51 per cent in Cronus Pharma cancelled
On August 12, the company had announced that it had entered into definitive agreements to subscribe to fresh equity shares in Hyderabad-based Cronus, a generic veterinary pharmaceutical products firm engaged in development, manufacturing and sale of these items.
Aurobindo Pharma to buy US animal health firm Cronus for Rs 420 cr
Hyderabad-based Cronus is engaged in development, manufacturing and sale of veterinary pharmaceutical products and has a large exposure in the US markets.
US-based Acasti Pharma to buy Indian origin pharma firm Grace
As per the understanding, Acasti will acquire Grace’s entire therapeutic pipeline consisting of three unique clinical stage and multiple pre-clinical stage assets, according to regulatory filings. The assets are supported by an intellectual property portfolio consisting of more than 40 granted and pending patents in various jurisdictions worldwide.
India seeks new preferential treatment from U.S. on drugs, other goods: Sources
India accounts for 40% of U.S. generic drug imports, including the anti-malarial hydroxychloroquine, touted by U.S. President Donald Trump in the fight against the coronavirus. To win preferential treatment on pharmaceutical exports, the govt of PM Narendra Modi is dangling the carrot of opening its dairy and farm markets to the Trump administration.
Buy Hikal, target Rs 218: HDFC Securities
Buy Hikal at a price target of Rs 218.
Eight Roads leads Rs 45 crore Series A funding round in Ashish Life Science
The investment is the second by the marquee investor in India's broader pharmaceutical sector.
Government to frame new rules on medical devices to draw investments
India is the largest provider of generic drugs globally, with the Indian generics accounting for 20 per cent of global exports in terms of volume.
Novartis India Q1 net profit falls 6% to Rs 13.45 crore
Drug firm Novartis India today reported six per cent fall in its standalone net profit at Rs 13.45 crore for the first quarter ended June 30, 2015.
Alembic Pharma, Hester Biosciences net profit jumps 25%, 66% respectively
Alembic Pharma’s net profit grew by 25% at Rs 77.3 crore for the Q2 FY14 against Rs 61.6 crore in corresponding quarter last fiscal.
Novartis revamps pharma world with mega-deals with GSK, Eli Lilly
The Swiss drugmaker said it would divest its vaccines business, excluding flu, to GSK for $7.1 million plus royalties.
India wants Russia to lift rice imports ban
Rice export to Russia rose five times to $25 million in April-December 2012.
Transgene Biotek joins hands with Mauritius-based FII, to delist shares
Transgene Biotek has announced that Stream Value Fund has agreed to join hands on a long-term basis to support its drug discovery activity.
Novartis India Q3 net dips 5.30 pc to Rs 38.35 cr
The company had posted a net profit of Rs 40.50 crore for the quarter ended December 31, 2010 Novartis India said in a filing to BSE.
Pfizer: No immediate cure seen for short-term hiccups
Pfizer India, the Indian arm of the US drug major Pfizer Inc, reported muted performance for the four months ended March 2011.
Lupin settles litigation over Lunesta with Japanese firm
Drug firm Lupin on Monday said it has settled ongoing litigation over Lunesta tablets, used in treating insomnia, with Japan-based Dainippon Sumitomo Pharma.
Sanofi plans mega US deal to counter sales dip
Sanofi-Aventis, France’s biggest drugmaker, is preparing a major acquisition in the US, according to five people with knowledge of the situation.
Sanofi to acquire Chattem, expand presence in US
Sanofi-aventis agreed to buy Chattem, the maker of Gold Bond medicated body powder, for $1.9 billion to enter the US consumer health care market.
Global drug cos set sights on India’s veterinary market
Animal healthcare in India is no longer an afterthought, as global pharmaceutical companies facing loss in revenues due to expiring drug patents are looking for new growth markets.
Pfizer to license generics from India's Aurobindo
Pfizer Inc has agreed to license an array of generic pills and injectable medicines from India's Aurobindo Pharma Ltd as the world's largest drugmaker looks to off-patent medicines for growth.
Pharma cos on lookout for Indian drug firms
A host of global pharmaceutical companies including the world's largest drugmaker Pfizer, GlaxoSmithKline (GSK) and Sanofi Aventis are scouting to buy Indian drug firms in a bid to expand into generics market and boost flagging sales.
Good days are here to stay for drug makers
The pharmaceutical sector, which has recorded a strong performance in the past two consecutive quarters, is again set to report strong numbers in the quarter ended December 2006.
Patent regime unlikely to benefit developing nations: UK report
The commission on intellectual property rights set up by the British government to look into the impact of an international IPR regime, has said that the global expansion of IPR was unlikely to generate significant benefits for most developing countries.
Load More
